Syncom Formulations Announces Results of 38th AGM Voting
Syncom Formulations held its 38th AGM on September 30, 2026. Results of e-voting were declared on October 1, 2026. Resolutions passed include adoption of financial statements, declaration of a 10% dividend (₹0.10 per share), and re-appointments/confirmations of directors and key management personnel.
The passing of resolutions related to financial statements, dividend declaration, and director appointments are material events for the company.
The announcement details the successful conclusion of the AGM with all resolutions passed, including the declaration of a dividend and key managerial appointments.
Syncom Formulations (India) Limited announced the results of the remote e-voting and e-voting conducted at its 38th Annual General Meeting (AGM), which was held on September 30, 2026. The meeting commenced at 2:00 PM IST and concluded at 2:42 PM IST via Video Conferencing and Other Audio Visual Means (VC/OAVM).
The Chairman declared the results on October 1, 2026, based on the Scrutinizer's report. The company is in the process of filing these results in XBRL mode and has enclosed the Scrutinizer's Report for records.
Key resolutions passed during the AGM included the adoption of the Standalone and Consolidated Audited Financial Statements for the financial year ended March 31, 2026, along with the Board and Auditors' reports. A dividend of 10%, or ₹0.10 per equity share of face value ₹1, for the financial year ended March 31, 2026, was also declared. Re-appointments and confirmations of several key personnel were approved: Mr. Ankit Kedarmal Bankda as Director, Mr. Rahul Vijay Bankda as Director and Managing Director, and Mrs. Rinki Ankit Bankda as Director and Whole-Time Director. The remuneration for Mr. Ankur Vijay Bankda, Chief Financial Officer, was approved for an increase, and Mrs. Ruchi Jindal was re-appointed as a Woman Independent Director for a second term. The remuneration payable to the Cost Auditor, M/s. M. Goyal & Co., for the financial year 2026-27 was also ratified.
What to do with a filing like this
Syncom Formulations (India) Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Syncom Formulations (India) Limited. Read the original for the full detail.